Anti-Human GAPDH (NT)

Anti-Human GAPDH (NT)

Product No.: G626

[product_table name="All Top" skus="G626"]

- -
- -
Target
GAPDH
Product Type
Polyclonal Antibody
Alternate Names
Glyceraldehyde-3-Phosphate Dehydrogenase, G3PDH, GAPD
Applications
IHC FFPE
,
WB

- -
- -
Select Product Size

Data

- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Rabbit
Immunogen
PN:G628
Product Concentration
0.5 mg/ml
Formulation
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Storage and Handling
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day Ambient
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Rabbit Anti-Human GAPDH recognizes an epitope near the amino-terminus of human, mouse and rat GAPDH. This polyclonal antibody was purified using affinity chromatography.
Background
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) catalyzes the reversible oxidative phosphorylation of glyceraldehyde-3-phosphate in the presence of inorganic phosphate and nicotinamide adenine dinucleotide (NAD), an important energy-yielding step in carbohydrate metabolism. Recent evidence suggests that it also is involved in a number of cellular processes such as membrane fusion, phosphotransferase activity, DNA replication and repair, and nuclear RNA export (1). GAPDH has also been implicated in playing a role in different pathologies such as cancer progression, apoptosis, and neuronal diseases such as Alzheimer’s and Huntington’s disease (2). GAPDH is constitutively expressed at high levels in almost all tissues and cell lines making it ideal for use as a loading control marker in immunoblots.
PubMed

References & Citations

1. Sirover, MA. (2005) J. Cell. Biochem. 95:45
2. Senatorov, V. et al. (2005) Annu. Rev. Pharmacol. Toxicol. 45:269-90.
IHC FFPE
General Western Blot Protocol

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.